Department of Cardiovascular Surgery, The Second Hospital, Jilin University, Chang Chun, China.
J Transl Med. 2012 Jan 4;10:2. doi: 10.1186/1479-5876-10-2.
Proliferation and migration of vascular smooth muscle cells (VSMCs) play a key role in neointimal formation which leads to restenosis of vein graft in venous bypass. STAT-3 is a transcription factor associated with cell proliferation. We hypothesized that silencing of STAT-3 by siRNA will inhibit proliferation of VSMCs and attenuate intimal thickening.
Rat VSMCs were isolated and cultured in vitro by applying tissue piece inoculation methods. VSMCs were transfected with STAT 3 siRNA using lipofectamine 2000. In vitro proliferation of VSMC was quantified by the MTT assay, while in vivo assessment was performed in a venous transplantation model. In vivo delivery of STAT-3 siRNA plasmid or scramble plasmid was performed by admixing with liposomes 2000 and transfected into the vein graft by bioprotein gel applied onto the adventitia. Rat jugular vein-carotid artery bypass was performed. On day 3 and7 after grafting, the vein grafts were extracted, and analyzed morphologically by haematoxylin eosin (H&E), and assessed by immunohistochemistry for expression of Ki-67 and proliferating cell nuclear antigen (PCNA). Western-blot and reverse transcriptase polymerase chain reaction (RT-PCR) were used to detect the protein and mRNA expression in vivo and in vitro. Cell apoptosis in vein grafts was detected by TUNEL assay.
MTT assay shows that the proliferation of VSMCs in the STAT-3 siRNA treated group was inhibited. On day 7 after operation, a reduced number of Ki-67 and PCNA positive cells were observed in the neointima of the vein graft in the STAT-3 siRNA treated group as compared to the scramble control. The PCNA index in the control group (31.3 ± 4.7) was higher than that in the STAT-3 siRNA treated group (23.3 ± 2.8) (P < 0.05) on 7d. The neointima in the experimental group(0.45 ± 0.04 μm) was thinner than that in the control group(0.86 ± 0.05 μm) (P < 0.05).Compared with the control group, the protein and mRNA levels in the experimental group in vivo and in vitro decreased significantly. Down regulation of STAT-3 with siRNA resulted in a reduced expression of Bcl-2 and cyclin D1. However, apoptotic cells were not obviously found in all grafts on day 3 and 7 post surgery.
The STAT-3 siRNA can inhibit the proliferation of VSMCs in vivo and in vitro and attenuate neointimal formation.
血管平滑肌细胞(VSMCs)的增殖和迁移在导致静脉移植后再狭窄的新内膜形成中起关键作用。STAT-3 是一种与细胞增殖相关的转录因子。我们假设通过 siRNA 沉默 STAT-3 将抑制 VSMCs 的增殖并减轻内膜增厚。
通过应用组织块接种方法,在体外分离和培养大鼠 VSMCs。使用脂质体 2000 将 STAT3 siRNA 转染入 VSMCs。通过 MTT 测定法体外定量 VSMC 的增殖,同时在静脉移植模型中进行体内评估。通过与脂质体 2000 混合并通过应用于外膜的生物蛋白凝胶将 STAT-3 siRNA 质粒或 scramble 质粒递送至静脉移植物中来进行体内递送。进行大鼠颈静脉-颈动脉旁路移植。在移植后第 3 天和 7 天,提取静脉移植物,通过苏木精-伊红(H&E)进行形态学分析,并通过免疫组织化学检测 Ki-67 和增殖细胞核抗原(PCNA)的表达进行评估。使用 Western blot 和逆转录聚合酶链反应(RT-PCR)检测体内和体外的蛋白和 mRNA 表达。通过 TUNEL 测定法检测静脉移植物中的细胞凋亡。
MTT 测定表明,STAT-3 siRNA 处理组的 VSMC 增殖受到抑制。在手术后第 7 天,与 scramble 对照组相比,STAT-3 siRNA 处理组的静脉移植物新内膜中 Ki-67 和 PCNA 阳性细胞的数量减少。对照组(31.3 ± 4.7)的 PCNA 指数高于 STAT-3 siRNA 处理组(23.3 ± 2.8)(P <0.05)。实验组(0.45 ± 0.04μm)的新内膜比对照组(0.86 ± 0.05μm)薄(P <0.05)。与对照组相比,实验组体内和体外的蛋白和 mRNA 水平均显著降低。用 siRNA 下调 STAT-3 导致 Bcl-2 和 cyclin D1 的表达减少。然而,在手术后第 3 天和第 7 天,所有移植物中均未明显发现凋亡细胞。
STAT-3 siRNA 可抑制体内和体外 VSMCs 的增殖,并减轻新内膜形成。